IPSC: Century Tx Net earnings per share (EPS TTM)

Public company logo of Century Tx (IPSC)

Earnings per share over the last 12 months demonstrate Century Therapeutics (IPSC) dependence on external capital due to a lack of market influence prior to the FDA verdict. The current level of -0.61 captures fresh values while the company relies on universal cell products for oncology centers. Growth prospects are supported by the patented iPSC platform and steady interest from venture capital funds in genetics.

IPSC (Century Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/15/2026

centurytx.com - analytical breakdowns and key metrics (IPSC)

- share price and expert price forecast:
Stock Quotes Century Therapeutics, Inc.|IPSC - Fair Value Consensus
- market capitalization information:
Market Capitalization IPSC|IPSC - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share Century Therapeutics|IPSC - Total Stockholders' Equity|Market Value to Book Value Ratio centurytx.com|IPSC - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Century Therapeutics|IPSC - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Century Therapeutics, Inc.|IPSC - Aggregate Debt Obligations|Debts to Book Capitalization Century Therapeutics Inc|IPSC - Long-Term Indebtedness|Company Short-Term Debts Century Therapeutics|Quick Liquidity centurytx.com
- net income and valuation multiples indicators:
IPSC - Company Profit|Projected Future Earnings Century Therapeutics|IPSC - Market Cap to Earnings|Projected Price to Earnings Century Therapeutics, Inc.|IPSC - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Century Therapeutics, Inc.|IPSC - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Century Therapeutics|IPSC - Earnings per share for the trailing year|Quarterly EPS earnings growth centurytx.com|IPSC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Century Therapeutics
- revenue and sales proceeds data:
IPSC - Company Sales Revenue|Projected Sales Volume Century Therapeutics|IPSC - P/S Multiple|Price-to-Projected Revenue Ratio Century Tx|IPSC - Trailing Twelve Months Sales Growth
General company analysis:Century Tx (IPSC)
Mass-produced product of Century Therapeutics

For Century Therapeutics (IPSC), the 12-month earnings per share history serves as an indicator of how effectively the company is capitalizing on its stem cell platform. This metric calculates the rolling annual net income distributed across the total shares outstanding. Such an approach eliminates quarterly gaps, demonstrating the actual dynamics of equity earnings. For this biotech firm, this indicator is critical as it transitions toward commercial procurement of cancer therapies by insurers. An upward trend in the curve would confirm the successful monetization of universal products.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (Sana Biotechnology, Inc.)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics Inc|RNAC (Selecta Biosciences) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cellectis.com CLLS|Earnings per share for the last twelve months Caribou Biosciences, Inc. (CRBU)|Earnings per share for the last twelve months TIL (Instil Bio, Inc)|Earnings per share for the last twelve months Genenta GNTA|jaspertherapeutics.com - Earnings per share for the last twelve months|SNTI: Net earnings per share for the last 12 months|Earnings per share for the trailing year ADAP (adaptimmune.com)|CERO: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Alaunos Therapeutics Inc. TCRT|ACHL (Achilles Therapeutics PLC) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CARGO Therapeutics, Inc CRGX|Earnings per share for the last twelve months Poseida Therapeutics, Inc. (PSTX)|2seventy bio, Inc. - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell)